NAD+ cycle refers to two completely unrelated things, and searching for one reliably returns the other. The first is a genuine piece of biochemistry, a molecule that alternates between two states thousands of times a day inside every cell. The second is a dosing schedule borrowed from steroid vocabulary, with no evidence behind it for this compound.
The vendor we point lifters to
NAD+ from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 20, 2026.
Separating them removes most of the confusion, and what remains has a short answer.
| The word cycle, used two ways | What it describes | Evidence behind it | Organism |
|---|---|---|---|
| The redox cycle | NAD+ accepting electrons to become NADH, then returning to NAD+ | Fundamental, established biochemistry | All species |
| The salvage cycle | NAD+ consumed by enzymes, released as nicotinamide, rebuilt into NAD+ | Established metabolic pathway | All species |
| An on and off dosing schedule | Weeks of use followed by planned breaks | No studies of this design for either form | None |
| A break to restore responsiveness | The assumption that response fades and returns | Tolerance of that kind is not described here | None |
| Cycling to protect an anabolic gain | The steroid model of use | Nothing anabolic exists here to protect | None |
The original meaning: a coenzyme that cycles
In its primary role NAD+ is an electron carrier, and cycling is literally what it does.
It accepts electrons stripped from fuel molecules during glycolysis and the citric acid cycle, becoming NADH. It delivers those electrons to the mitochondrial electron transport chain, where the energy is captured. Then it returns to the oxidised state, NAD+, ready to do it again. The molecule is not consumed in this role, and the useful quantity is the size of the pool that keeps turning over.
There is a second cycle running alongside it. Enzymes including the sirtuins, the PARPs involved in DNA repair, and CD38 consume NAD+ as a substrate, cleaving it and releasing nicotinamide. The salvage pathway rebuilds NAD+ from that nicotinamide, with the enzyme NAMPT setting the pace.
Both of these are real, both are continuous, and neither has anything to do with a schedule of weeks on and weeks off.
The NAD+ cycle people mean when they type it
The searched meaning is a use pattern: how long to take something, when to stop, whether breaks are needed.
That framing arrived from anabolic steroid practice, where cycling addressed specific problems: suppression of the body's own hormone production, receptor level adaptation, and cumulative strain that rises with continuous exposure. Off periods let a suppressed axis restart.
None of those problems is described for NAD+ or its precursors. There is no hormonal axis being suppressed, no reported tolerance requiring a washout, and no anabolic gain to defend during a break. The vocabulary crossed over because it was the vocabulary the audience already used, not because the underlying pharmacology called for it.
Why an on and off schedule has no rationale here
Three things would have to be true for cycling to make sense, and none of them is established.
Response would have to fade with continued use. That has not been reported for oral precursors or for injected NAD+ in humans. What is reported for oral precursors, repeatedly, is that blood NAD+ metabolites rise and stay raised while the compound is taken.
A break would have to restore something. There is nothing described that becomes depleted or desensitised by continuous use in a way that time off repairs.
And continuous exposure would have to carry a cumulative risk that intermittent use avoids. Long term data are absent for both forms, so this cannot be claimed in either direction. Absence of evidence is not a reason to design a schedule around it.
What the pathway does about excess
There is an argument sometimes made that the body regulates its own NAD+ and therefore extra input is wasted, and it is worth stating accurately rather than as a slogan.
Resynthesis is rate limited at NAMPT, so the salvage pathway does not simply scale with whatever arrives. Excess nicotinamide is also cleared, a process that consumes methyl groups, which is the basis of a theoretical concern about methyl donor use discussed in the literature rather than an established clinical problem.
What that supports is modest: the system is regulated rather than a container to be filled. It does not establish that supplementation is pointless, and it does not establish that a break helps. It is a reason to be sceptical of any schedule built on the idea of loading and unloading a reservoir, because the pathway does not appear to work that way.
What stopping would actually change
Blood NAD+ metabolites raised by oral precursors would be expected to return toward baseline once the precursor stops, since the rise reflects ongoing supply rather than a stored gain.
Beyond that, there is very little to describe, and the reason is worth stating plainly. The trials that would show what happens after discontinuation, in terms of any functional outcome, largely do not exist, because the functional outcomes themselves have been hard to demonstrate while people were still taking it.
You cannot lose on stopping what was never shown to be gained on starting. That sentence is unglamorous, and it is the accurate summary of the situation.
Nothing here is anabolic, which settles most of it
The cycling question in this readership usually carries an assumption underneath: that something was built and needs protecting.
No trial of oral precursors or of injected NAD+, in any species, has reported an increase in muscle mass or in strength. There is no described interaction with myostatin, with satellite cell behaviour or with muscle protein synthesis. The mechanism is energy metabolism and enzyme substrate supply, not growth signalling.
Trials of oral nicotinamide riboside in older adults have reported that NAD+ metabolites rose in blood while measured effects in skeletal muscle were limited or absent. That is the closest this field has come to testing the muscle question directly, and the result points away from an anabolic effect rather than toward one.
So there is nothing to preserve across a break, nothing to rebound during one, and no post cycle consideration of any kind.
The duration question, which is the one underneath
Strip out the borrowed schedule and a reasonable question remains: how long has anyone actually taken these compounds under observation?
For oral precursors, human trials have run for defined periods with defined populations, and within those periods tolerability was generally reported as good. That is a real answer with a boundary around it, and the boundary is the trial length rather than a person's intentions.
For injected NAD+ there is no equivalent answer, because there is no controlled record to derive one from. Clinics administer courses of infusions, but a course of appointments is a description of a business practice, not a study of duration.
So a reader asking how long to run something is asking a question the literature can partly answer for a capsule and cannot answer at all for a vial. That is a more useful thing to know than any number of weeks, and it is the honest shape of the uncertainty here.
The version of the question worth asking
Replace the schedule question with an evidence question and it becomes tractable.
Which molecule is being taken, and by which route? Most human trial evidence concerns oral precursors, and injected NAD+ has essentially no controlled record. What outcome would show that it is doing anything? Blood NAD+ has already been shown to move without the muscle following, so it cannot serve as the answer. And what would be lost by simply not doing it, given that training itself has been reported in humans to increase expression of the salvage pathway enzyme NAMPT in skeletal muscle?
Those questions have better answers than any schedule does, and they arrive at the same place: an interesting pathway, a real age related decline, and no demonstrated muscle outcome for either form.
Questions about cycling and stopping
Does anyone need to cycle NAD+ or its precursors?
No evidence supports a cycling structure for either form. Tolerance of the kind cycling was invented to manage is not described here.
Does the body stop responding to continued use?
Not as reported. Trials of oral precursors show blood NAD+ metabolites rising and remaining raised during use, which is the opposite of a fading response.
Is anything needed after stopping?
Nothing is described that requires recovery afterwards. There is no suppressed system and no anabolic gain at stake.
Does a break protect against long term harm?
Long term data are absent for both the oral and injected forms, so nothing supports that claim or refutes it. Designing a schedule around an unknown is not caution, it is invention.
Would stopping cost me muscle?
No study of either form has reported a muscle gain to lose. The compounds have not been shown to add muscle in any species, so discontinuation has nothing to reverse.